| Basics |
Merus N.V.
Merus NV is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics.
|
| IPO Date: |
May 19, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.52B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.61 | 2.78%
|
| Avg Daily Range (30 D): |
$1.50 | 3.25%
|
| Avg Daily Range (90 D): |
$1.29 | 2.97%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.22M |
| Avg Daily Volume (30 D): |
1.19M |
| Avg Daily Volume (90 D): |
.81M |
| Trade Size |
| Avg Trade Size (Sh.): |
85 |
| Avg Trade Size (Sh.) (30 D): |
82 |
| Avg Trade Size (Sh.) (90 D): |
72 |
| Institutional Trades |
| Total Inst.Trades: |
2,103 |
| Avg Inst. Trade: |
$1.82M |
| Avg Inst. Trade (30 D): |
$1.9M |
| Avg Inst. Trade (90 D): |
$1.82M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.92M |
| Avg Closing Trade (30 D): |
$2.82M |
| Avg Closing Trade (90 D): |
$2.49M |
| Avg Closing Volume: |
46K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-1.4
|
$-1.46
|
|
Diluted EPS
|
|
$-1.4
|
$-1.46
|
|
Revenue
|
$
|
$ 26.49M
|
$ 11.77M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -96.47M
|
$ -99.91M
|
|
Operating Income / Loss
|
$
|
$ -75.74M
|
$ -72.23M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -96.14M
|
$ -196.46M
|
|
PE Ratio
|
|
|
|
|
